HBI Deals+Insights / M&A/IPOs
Multiple sources have told HBI that fast-growing German and Swiss ophthalmology group Sanoptis might be looking at a Q2 sale, but HBI understands that is not entirely correct. HBI speaks to Sanoptis CEO Volker Wendel to set the record straight.





